… ProQR to Present its Axiomer® RNA Editing Technology at TIDES … & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR Appoints John Maraganore, PhD, as Strategic Advisor to … & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … if any,” said Daniel A. de Boer, Founder and CEO of ProQR. “As the founding CEO of Alnylam, he built and led one …
ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy
… ProQR to Present Axiomer RNA Editing Platform Technology at … & CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … Platenburg, co-founder and Chief Innovation Officer of ProQR. “With this approach disease-causing mutations can be …
ProQR erhält die exklusive weltweite Lizenz für IONIS-RHO-2.5Rx, jetzt QR-1123, für autosomal-dominante Retinitis pigmentosa (adRP), eine seltene vererbte Form der Blindheit ohne zugelassene Therapie